FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 17, 2026
Capricor Therapeutics, Inc. (CAPR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $105.0 million. Free cash flow was -$72.7 million. As of Jun 30, 2026 it held $237.9 million in cash and investments and $91.0 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-105.04M
-159.6% vs prior year
Operating cash flow (TTM)
$-104.00M
-96.2% vs year-ago TTM
Free cash flow (TTM)
$-114.90M
-110.1% vs year-ago TTM
EPS
$-2.26
-96.5% vs prior year
Dividend per share
None
Shares outstanding
57.51M
+25.9% vs prior year
Net cash
$146.89M
as of Jun 30, 2026
Operating margin
-191.1%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CAPR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1133869
- Former names
- Nile Therapeutics, Inc. (until Nov 20, 2013); SMI PRODUCTS INC (until Sep 19, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $22.3M | $25.2M | $2.6M | $244,898 |
| Operating income | -$108.1M | -$42.6M | -$24.1M | -$29.7M | -$20.9M |
| Net income | -$105.0M | -$40.5M | -$22.3M | -$29.0M | -$20.0M |
| Diluted EPS | -$2.26 | -$1.15 | -$0.83 | -$1.18 | -$0.87 |
| Operating cash flow | -$69.8M | -$40.0M | -$25.6M | $4.9M | -$16.8M |
| Free cash flow | -$72.7M | -$41.2M | -$26.9M | $2.9M | -$18.0M |
| Total assets | $355.9M | $170.5M | $58.7M | $50.1M | $41.3M |
| Total liabilities | $50.2M | $25.0M | $36.1M | $38.3M | $10.0M |
| Stockholders' equity | $305.8M | $145.5M | $22.6M | $11.8M | $31.4M |
| Cash and investments | $318.1M | $151.5M | $39.5M | $41.4M | $34.9M |
| Total debt | $14.5M | $1.5M | $2.2M | $2.2M | $2.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 24, 2026 | Aug 24, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Other events
|
Jul 30, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Other events
|
Jul 29, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 14, 2026 | Jul 9, 2026 |
All 963 Capricor Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.